1. Home
  2. KSS vs IMNM Comparison

KSS vs IMNM Comparison

Compare KSS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kohl's Corporation

KSS

Kohl's Corporation

HOLD

Current Price

$18.63

Market Cap

2.4B

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$22.66

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KSS
IMNM
Founded
1962
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.2B
IPO Year
1992
2020

Fundamental Metrics

Financial Performance
Metric
KSS
IMNM
Price
$18.63
$22.66
Analyst Decision
Sell
Strong Buy
Analyst Count
14
9
Target Price
$16.08
$31.22
AVG Volume (30 Days)
3.5M
2.5M
Earning Date
11-25-2025
11-06-2025
Dividend Yield
2.69%
N/A
EPS Growth
N/A
N/A
EPS
1.73
N/A
Revenue
$15,751,000,000.00
$9,679,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$11.53
P/E Ratio
$10.76
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.04
$5.15
52 Week High
$25.22
$25.30

Technical Indicators

Market Signals
Indicator
KSS
IMNM
Relative Strength Index (RSI) 38.77 60.67
Support Level $19.28 $20.05
Resistance Level $20.67 $22.01
Average True Range (ATR) 1.15 1.28
MACD -0.36 0.04
Stochastic Oscillator 3.55 82.00

Price Performance

Historical Comparison
KSS
IMNM

About KSS Kohl's Corporation

Kohl's operates about 1,150 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also has a large digital sales operation. Women's apparel is Kohl's largest category, having generated 25% of its 2024 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Share on Social Networks: